1481-92-1

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-Hydroxy-propyl)-phenol is used as a precursor in the synthesis of pharmaceuticals for its ability to be chemically modified to create a range of medicinal compounds. Its versatility in chemical reactions makes it a valuable component in the development of new drugs.
Used in Agricultural Chemicals Industry:
In the agricultural sector, 2-(3-Hydroxy-propyl)-phenol is utilized as a starting material for the production of various agricultural chemicals, contributing to the development of pesticides and other agrochemicals that enhance crop protection and yield.
Used as a Disinfectant:
2-(3-Hydroxy-propyl)-phenol is employed as a disinfectant in various products due to its ability to eliminate or inactivate pathogens, making it suitable for use in sanitizing applications across different industries.
Used as a Preservative:
2-(3-HYDROXY-PROPYL)-PHENOL also serves as a preservative, helping to prevent the spoilage of products by inhibiting the growth of microorganisms, thereby extending the shelf life of various goods in the market.

InChI:InChI=1/C9H12O2/c10-7-3-5-8-4-1-2-6-9(8)11/h1-2,4,6,10-11H,3,5,7H2

Upstream product

• 91-64-5 coumarin 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 61632-76-6 3-(o-acetoxyphenyl)propyl acetate 
• 89113-48-4 1-methoxy-2-(3-methoxy-propyl)-benzene 
• 7585-39-9 β‐cyclodextrin 
• 60-29-7 diethyl ether 
• 3943-94-0 (E)-ethyl 2-hydroxycinnamate 
• 201230-82-2 carbon monoxide 
• 14864-24-5 (Z)-2-(3-hydroxyprop-1-en-1-yl)phenol 
• 20349-89-7 methyl 3-(2-hydroxyphenyl)propionate 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 129967-36-8 4-Methoxyaniline 3-(2'-(Benzyloxy)phenyl)propionic Acid Amide 
• 129967-35-7 phenylmethyl 3-[(4-phenylmethoxy)phenyl]propanoate 
• 19844-20-3 4-Methoxyaniline 3-(2'-Hydroxyphenyl)propionic Acid Amide 

Downstream Products

• 10493-37-5 3-(2-methoxyphenyl)propan-1-ol 
• 110166-31-9 3-(o-diphenylphosphinylmethoxyphenyl)propanol 
• 119-84-6 C₆H₄(CH₂CH₂C(O)O) 
• 157872-81-6 1-(1,3-Dioxabutyl)-2-(4,6-dioxaheptyl)benzol 
• 81246-46-0 3-(2-hydroxyphenyl)-1-propyl tosylate 
• 71238-44-3 3-[2-(2,4-Dichloro-benzyloxy)-phenyl]-propan-1-ol 
• 215245-07-1 3-{2-[3-(4-Benzyloxy-phenyl)-propoxy]-phenyl}-propan-1-ol 
• 208118-65-4 2-(3-hydroxypropyl)phenyl benzoate 
• 110166-32-0 3-(o-diphenylphosphinylmethoxyphenyl)propyltosylate 
• 58621-52-6 1-<6-(3,4-dihydro-2H-1-benzopyranyl)>ethanone 
• 81246-44-8 3-(2-hydroxyphenyl)-1-propyl p-nitrophenyl sulfide 
• 81246-48-2 3-(2-methoxyphenyl)-1-propyl p-nitrophenyl sulfide 
• 81246-47-1 1-(para-toluenesulfonyl)-3-(2-methoxyphenyl)propane 
• 81246-41-5 C₁₆H₁₈NO₃S⁽¹⁺⁾*BF₄^(1-) 

Relevant academic research and scientific papers

Selectivity in sodium borohydride reduction of coumarin encapsulated in β-cyclodextrin

The sodium borohydride reduction of coumarin to the corresponding alkanol and alkenol has been investigated in the presence and absence of β-cyclodextrin (β-CD). Excellent selectivity is observed when β-CD-coumarin complex is reduced in solid state at 0°C and the alkenol, cis-o-hydroxycinnamyl alcohol is the major product. Complex formation and the mode of substrate insertion into the CD cavity have been analysed using various physical methods.

A ring size-selective reduction of lactones using SmI2 and H2O

The SmI2-H2O reducing system shows complete selectivity for six-membered lactones over other classes of lactone and esters. Experimental and computational studies suggest that the origin of the selectivity lies in the initial electro

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY

The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

Towards practical earth abundant reduction catalysis: Design of improved catalysts for manganese catalysed hydrogenation

Manganese catalysts derived from tridentate P,N,N ligands can be activated easily using weak bases for both ketone and ester hydrogenations. Kinetic studies indicate the ketone hydrogenations are 0th order in acetophenone, positive order in hydrogen and 1st order in the catalyst. This implies that the rate determining step of the reaction was the activation of hydrogen. New ligand systems with varying donor strength were studied and it was possible to make the hydrogen activation significantly more efficient; a catalyst displaying around a 3-fold increase in initial turn-over frequencies for the hydrogenation of acetophenone relative to the parent system was discovered as a result of these kinetic investigations. Ester hydrogenations and ketone transfer hydrogenation (isopropanol as reductant) are first order for both the substrate and catalysts. Kinetic studies also gained insight into catalyst stability and identified a working range in which the catalyst is stable throughout the catalytic reaction (and a larger working range where high yields can still be achieved). The new more active catalyst, combining an electron-rich phosphine with an electron-rich pyridine is capable of hydrogenating acetophenone using as little as 0.01 mol% catalyst at 65 °C. In all, protocols for reduction of 21 ketones and 15 esters are described.

Probing the Existence of a Metastable Binding Site at the β2-Adrenergic Receptor with Homobivalent Bitopic Ligands

Herein, we report the development of bitopic ligands aimed at targeting the orthosteric binding site (OBS) and a metastable binding site (MBS) within the same receptor unit. Previous molecular dynamics studies on ligand binding to the β2-adrenergic receptor (β2AR) suggested that ligands pause at transient, less-conserved MBSs. We envisioned that MBSs can be regarded as allosteric binding sites and targeted by homobivalent bitopic ligands linking two identical pharmacophores. Such ligands were designed based on docking of the antagonist (S)-alprenolol into the OBS and an MBS and synthesized. Pharmacological characterization revealed ligands with similar potency and affinity, slightly increased β2/β1AR-selectivity, and/or substantially slower β2AR off-rates compared to (S)-alprenolol. Truncated bitopic ligands suggested the major contribution of the metastable pharmacophore to be a hydrophobic interaction with the β2AR, while the linkers alone decreased the potency of the orthosteric fragment. Altogether, the study underlines the potential of targeting MBSs for improving the pharmacological profiles of ligands.

Design, Synthesis, and Cellular Uptake of Oligonucleotides Bearing Glutathione-Labile Protecting Groups

Glutathione-labile protecting groups for phosphodiester moieties in oligonucleotides were designed, synthesized, and incorporated into oligonucleotides. The protecting groups on the phosphodiester moieties were cleaved in a buffer containing 10 mM glutath

Synthesis and PGE2 inhibitory activity of novel diarylheptanoids

Prostaglandin E2 (PGE2) is a lipid mediator of inflammation and its inhibition has become a popular drug target due to its harmful physiological roles. Diarylheptanoids are one class of compounds that have shown successful inhibition of PGE2. This paper reports the synthesis and PGE2 inhibitory activity of a series of analogues of a naturally occurring diarylheptanoid. The most efficacious compounds were examined for dose-dependent PGE2 inhibition. Among several promising compounds, the lead candidate exhibited an IC50 value of 0.56 ng/μL or 1.7 μM with no detectable toxicity at the highest dose of 10 ng/μL.

Ti-Catalyzed Synthesis of Exocyclic Allenes on Oxygen Heterocycles

A general method for the straightforward synthesis of exocyclic allenes on five-, six-, seven-, and eight-membered oxygen heterocycles is described. A Barbier-type titanocene(III)-catalyzed cyclization of propargyl halides with a pendant carbonyl group is

Coordination Chemistry of an Unsymmetrical Naphthyridine-Based Tetradentate Ligand toward Various Transition-Metal Ions

An unsymmetrical ligand, 2-(2-pyridinyl)-7-(pyrazol-1-yl)-1,8-naphthyridine (L5) was prepared for the construction of a series of dinuclear complexes. Treatment of L5with [Ru2(μ-OAc)4Cl] followed by anion metathesis afforded [(L5)(μ-OAc)3Ru2](PF6) (3). Reaction of L5with 2 equiv. of Ni(OAc)2provided [Ni4(L5)2(μ-OH)4(CF3COO)2](CF3COO)2(5). Reaction of [Re2(CO)8(CH3CN)2] with L5in a refluxing chlorobenzene solution gave a mixture of dirhenium (6) and monorhenium (7) complexes. The monocobalt complex 8 was obtained from complexation of L5with CoCl2. These new complexes were characterized by elemental analysis and spectroscopic techniques. The structures of complexes 3, 5 and 8 were further confirmed by X-ray crystallography. Nickel complex 5 was evaluated as a catalyst for reduction reactions involving the conversion of ester functionalities into their corresponding alcohols.